George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Stephen Diggle is the Founder and CEO of Vulpes Investment Management, a family office-backed investment manager. Let me provide you with more details about his background:
Stephen Diggle has been working in finance since 1986.
He spent 15 years working at international investment banks in London, Sydney, and Hong Kong.
He was one of the two founders of Artradis Fund Management, a Singapore-based hedge fund company that launched in 2002 with US$4 million and peaked at nearly US$5 billion late in 2008.
Artradis was multi-award-winning and, for some time, the largest and most successful hedge fund in Asia, making US$2.7 billion for investors between 2002 and 2009, especially during the financial crisis of 2008.
Following the success of Artradis, Stephen founded Vulpes Investment Management in 2011. Vulpes is a diversified family office-led investment company that runs a diverse portfolio of assets.
Vulpes has been an early investor in companies such as Scancell and Oxford Biomedica, providing capital at critical times to keep these companies afloat.
Stephen holds a Master’s degree from the University of Oxford in Philosophy, Politics, and Economics1.
Stephen Diggle’s expertise in finance and his passion for finding undervalued biotech firms make him a significant player in the investment world.
vulpesinvest.com
bing.com
4
pilgrimammunition.com
5
pitchbook.com
What other companies has Vulpes invested in?
Tell me more about Artradis Fund Management.
How can I contact Stephen Diggle?
Chats
Plug-ins
Copilot GPTs
Copilot
Copilot
Designer
Designer
Vacation planner
Vacation planner
Cooking assistant
Cooking assistant
Fitness trainer
Fitness trainer
Recents
Stephen Diggle: Vulpes CEO and Investment Expert
Write about flavors and tastes or a favorite spice of yours
Yesterday
UK Companies Developing Sepsis Diagnostic Tests
2 days ago
Response stopped
New topic
Derived from my copilot AI search
Yes, Alma Maritime Group is indeed using Ceres’ Solid Oxide Fuel Cell (SOFC) technology in its new vessel. Alma Maritime Group and Ceres have announced a collaboration to demonstrate an 80kW LNG fuelled system in 2024
Ceres will provide solid oxide fuel cell stacks for the development and validation of the power system. Meanwhile, Alma will develop and build the 80kW system that will be tested during 2024 in Stord, Norway, before being transferred to a vessel for further testing
The partnership aims to combine Ceres’ highly efficient technology with Alma’s marine systems development capabilities and market access. This collaboration is expected to drive the transition to a greener future for shipping
ALSO
Alma Maritime Group, in collaboration with Hydrogenious LOHC Technologies and Hydrogenious LOHC Maritime, has announced a joint development agreement to engineer a fully integrated LOHC-SOFC (Liquid Organic Hydrogen Carrier-Solid Oxide Fuel Cell) power system12. This is a first-of-its-kind system for maritime use.
The project, supported by Enova, focuses on a 100-kilowatt pilot powertrain to be demonstrated on board the Østensjø Rederi operated offshore supply vessel Edda Ferd2. The innovation combines hydrogen release from the LOHC with direct conversion into power by an adjacent SOFC unit to the benefit of high efficiency. The key to this lies in using the SOFC device’s excess heat to meet the LOHC release unit’s heat demand.
Hydrogenious’ LOHC solution provides a safe and easy method for handling hydrogen as a fuel, facilitating the decarbonisation of the maritime industry. The agreements also open up for hydrogen-powered vessels on megawatt-scale later.
This partnership leverages synergies between Alma’s SOFC solution and Hydrogenious LOHC technology, taking the next milestone in pioneering the use of hydrogen as a safe and efficient zero emission fuel to ships
@ CJ39
I think you are correct Stalica if you read their research there is a great unmet need for neurological drugs for conditions such as ASD Trials of recently tested drugs have failed to meet their endpoints with “The one size fits all approach “and a stratification approach is required for investigation with novel drugs This is where I think Stalica are desperate to get Evgen but on cheap !
Info@jpjenkins.com
anybody still confused like me about Match Bargain Facility dealing contact the above are very helpful .H&L staff when I contacted them seem to a bit vague about the process but JP Jenkins reassured me they will be processing delisted REDX and ETX from H& L GLA
@moniman @mthomas
Thanks for your info much appreciated
FWIW last opportunity to vote today .I had an email from Hargreaves & L to vote yesterday .Also they told me that my Redx shares they would be remove the shares from my ISA to my non ISA trading account at the time of delisting .It's not clear what happens then will I be able to sell or not or would it be better to sell before the 19th within the ISA preserving the cash tax benefit .Then at what price ! Hunt said invest in ISA British Companies .He didn't mention you might be mugged off absolute day light robbery never again got Etx to contend with next Appreciate comment from other share holders GLA
Https://www.propharmagroup.com/thought-leadership/fda-expedited-approvals
More on fast tracking
@B2H
"I could understand this patient, who must be due a scan shortly, must be feeling great to be alive, but possibly nonplussed to find the reduction in his tumour diameters were from 65% to only 74%."
From my research in general terms the tumour will probably will appear in the next scan but after prolonged chemo if it has not grown further then with 74% or more shrinkage might be considered non evasive and will not spread .Some tumours disappear spontaneously after infection but this phenomenon is not understood
For the most serious diseases where there is a great unmet need the FDA have a fast track process providing there drug is safe and effective (there are many examples ). IMO I think because DOX is already an approved drug we only need to optimise efficacy , dosage and demonstrate reduced toxicity of AVA6000 through P2 to convince FDA to trigger approval 'AS sounds very confident on the ground breaking data and yes P3 trials would provide transformational data using different more powerful war heads and drug combinations Very exciting prospects for share holders and benefits to cancer suffers AMHO gla
Why has William Black bought 4M cheap shares in our little pharma company ?He must know something , a quick buck or exciting potential drug development ? Hopefully not eventual privatisation like my other investments like REDX & ETX
Https://www.bbc.co.uk/news/health-68762171
Remember this from September 2022
Professor Chris Brightling, NIHR Senior Investigator, Department of Respiratory Sciences at the University of Leicester,said: "This promising Long COVID data is very welcome in an area of enormous clinical need. While it merits further investigation, it is exciting to see that SNG001 may have a positive effect in reducing some of the most recognised and problematic symptoms associated with Long COVID which afflicts millions of people and for which there are no current treatments."
It all appears encouraging from the abstract on the TME/plasma levels and safety .The reason why AS was pulled back on his over enthusiasm imo because there is still a lot of work to be done to optimise the DLT and provide the greatest benefit of the treatment . AVA 6000 has change the treatment characteristics is it more or less short or long dosage , improved efficacy over standard Dox . Further data required hence further clinical trials it is moving in the right direction for sure when that data is achieved AS can start shouting from the roof tops
Another Theranos another Elizabeth Holmes’s ? despicable another of my Aim shares mugged me off
China's President Xi Jinping makes the front of the Financial Times as he is pictured in Beijing meeting US business figures. The paper notes Beijing is seeking to revive investors' confidence in the country amid tensions with the US continuing to flare. The broadsheet leads with big takeovers more than doubling in the first quarter of this year "signalling a nascent recovery in mergers and acquisitions after a long drought".